Ya-Ching Lu1, Joseph Tung-Chieh Chang2, Yu-Chen Huang3, Chi-Che Huang4, Wen-Ho Chen3, Li-Yu Lee5, Bing-Shen Huang2, Yin-Ju Chen1, Hsiao-Fang Li1, Ann-Joy Cheng6. 1. Department of Medical Biotechnology, Medical College, Chang Gung University, 259 Wen-Hwa 1st Road, Taoyuan 333, Taiwan. 2. Department of Radiation Oncology, Chang Gung Memorial Hospital, Chang Gung University, 5. Fu-Hsing Street. Kuei-Shan, Taoyuan 333, Taiwan. 3. Department of Oral Maxillofacial Surgery, Chang Gung Memorial Hospital, 5. Fu-Hsing Street. Kuei-Shan, Taoyuan 333, Taiwan. 4. Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital, 5. Fu-Hsing Street. Kuei-Shan, Taoyuan 333, Taiwan. 5. Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, 259 Wen-Hwa 1st Road, Taoyuan 333, Taiwan. 6. Department of Medical Biotechnology, Medical College, Chang Gung University, 259 Wen-Hwa 1st Road, Taoyuan 333, Taiwan. Electronic address: ajchen@mail.cgu.edu.tw.
Abstract
OBJECTIVES: The aim of this study was to determine whether the oncogenic microRNA family members miR-196a and miR-196b can be circulating biomarkers for the early detection of oral cancer. DESIGN AND METHODS: To determine the stability of circulating miRNA, the blood sample was aliquot and stored at different temperature conditions for analysis. To assess the diagnostic efficacy, we determined the levels of miR-196s in plasma samples, including 53 from healthy individuals, 16 from pre-cancer patients, and 90 from oral cancer patients. RESULTS: In general, circulating miRNA was very stable when storing plasma samples at -20°C or below. In clinical study, both circulating miR-196a and miR-196b were substantially up-regulated in patients with oral pre-cancer lesions (5.9- and 14.8-fold, respectively; P < 0.01), as well as in oral cancer patients (9.3- and 17.0-fold, respectively; P < 0.01). These results show prominent discrimination between normal and pre-cancer patients (AUC = 0.764 or 0.840, miR-196a or miR-196b, respectively), and between normal and cancer patients (AUC = 0.864 or 0.960, miR-196a or miR-196b, respectively). The combined determination of miR-196a and miR-196b levels produces excellent sensitivity and specificity in the diagnosis of patients with oral pre-cancer (AUC = 0.845) or oral cancer (AUC = 0.963), as well as in the prediction of potential malignancy (AUC = 0.950, sensitivity = 91%, specificity = 85%). CONCLUSION: Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
OBJECTIVES: The aim of this study was to determine whether the oncogenic microRNA family members miR-196a and miR-196b can be circulating biomarkers for the early detection of oral cancer. DESIGN AND METHODS: To determine the stability of circulating miRNA, the blood sample was aliquot and stored at different temperature conditions for analysis. To assess the diagnostic efficacy, we determined the levels of miR-196s in plasma samples, including 53 from healthy individuals, 16 from pre-cancerpatients, and 90 from oral cancerpatients. RESULTS: In general, circulating miRNA was very stable when storing plasma samples at -20°C or below. In clinical study, both circulating miR-196a and miR-196b were substantially up-regulated in patients with oral pre-cancer lesions (5.9- and 14.8-fold, respectively; P < 0.01), as well as in oral cancerpatients (9.3- and 17.0-fold, respectively; P < 0.01). These results show prominent discrimination between normal and pre-cancerpatients (AUC = 0.764 or 0.840, miR-196a or miR-196b, respectively), and between normal and cancerpatients (AUC = 0.864 or 0.960, miR-196a or miR-196b, respectively). The combined determination of miR-196a and miR-196b levels produces excellent sensitivity and specificity in the diagnosis of patients with oral pre-cancer (AUC = 0.845) or oral cancer (AUC = 0.963), as well as in the prediction of potential malignancy (AUC = 0.950, sensitivity = 91%, specificity = 85%). CONCLUSION: Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
Authors: Mario Dioguardi; Stefania Cantore; Diego Sovereto; Lucia La Femina; Giorgia Apollonia Caloro; Francesca Spirito; Salvatore Scacco; Michele Di Cosola; Lorenzo Lo Muzio; Giuseppe Troiano; Andrea Ballini Journal: Life (Basel) Date: 2022-08-19
Authors: Zujian Chen; Tianwei Yu; Robert J Cabay; Yi Jin; Ishrat Mahjabeen; Xianghong Luan; Lei Huang; Yang Dai; Xiaofeng Zhou Journal: Biomark Cancer Date: 2017-01-09